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Abstract: Background: The success of programs to
eliminate lymphatic filariasis (LF) depends in large part
on their ability to achieve and sustain high levels of
compliance with mass drug administration (MDA). This
paper reports results from a comprehensive review of
factors that affect compliance with MDA.
Methodology/Principal Findings: Papers published be-
tween 2000 and 2012 were considered, and 79 publica-
tions were included in the final dataset for analysis after
two rounds of selection. While results varied in different
settings, some common features were associated with
successful programs and with compliance by individuals.
Training and motivation of drug distributors is critically
important, because these people directly interact with
target populations, and their actions can affect MDA
compliance decisions by families and individuals. Other
important programmatic issues include thorough prepa-
ration of personnel, supplies, and logistics for implemen-
tation and preparation of the population for MDA.
Demographic factors (age, sex, income level, and area of
residence) are often associated with compliance by
individuals, but compliance decisions are also affected
by perceptions of the potential benefits of participation
versus the risk of adverse events. Trust and information
can sometimes offset fear of the unknown. While no
single formula can ensure success MDA in all settings, five
key ingredients were identified: engender trust, tailor
programs to local conditions, take actions to minimize the
impact of adverse events, promote the broader benefits
of the MDA program, and directly address the issue of
systematic non-compliance, which harms communities by
prolonging their exposure to LF.
Conclusions/Significance: This review has identified
factors that promote coverage and compliance with
MDA for LF elimination across countries. This information
may be helpful for explaining results that do not meet
expectations and for developing remedies for ailing MDA
programs. Our review has also identified gaps in
understanding and suggested priority areas for further
research.
Introduction
The Global Programme to Eliminate Lymphatic Filariasis
(GPELF) is one of the most ambitious, exciting, and challenging
public health programs of our time. Part of the challenge is in the
large numbers of people that either have lymphatic filariasis (LF)
(an estimated 120 million) or who are at risk for the disease (1.39
billion) [1,2]. Like many other neglected tropical diseases (NTDs),
LF disproportionately affects vulnerable populations and perpet-
uates existing relationships between disease and poverty [3]. The
economic effects of LF can be devastating, as sufferers with
disfigurement and disability due to lymphedema, hydrocele, and
elephantiasis have reduced work capacity and household income
[4]. The ripple effects of this loss of income limit the ability to pay
for healthcare, education, and basic household expenses. The
social effects of the disease can be equally devastating, potentially
ostracizing people from their communities and families [5].
In 1997, the World Health Assembly targeted LF for
elimination as a public health problem by the year 2020 [6].
The main tool for GPELF is repeated, annual mass drug
administration (MDA) of antifilarial drugs to people living in
endemic areas [7,8]. According to guidelines put forward by the
World Health Organization (WHO), at least 65% of the at-risk
population should comply with annual MDA so that elimination
targets can be reached within four to six years (WHO-GPELF).
Implementation of MDA requires cooperation and coordination
of activities by donors, national and local health officials, non-
governmental organizations (NGOs), and communities.
GPELF is currently active in 53 of 73 countries that are
endemic for LF [9]. More than 536 million people received MDA
in 2011, and this success depended on the coordinated efforts of
the donor community, health ministries, community volunteers,
NGOs, and research institutions [9]. GPELF guidelines require
high compliance with MDA, but in practice this can be difficult to
achieve and sustain. It can be challenging to convince people who
feel well to take repeated doses of medicines that may cause
adverse events [10]. Emerging challenges to GPELF include
program fatigue, knowing what to do when elimination targets
have not been reached after six years of MDA, identifying and
targeting systematic non-compliers, and maintaining momentum
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Securing participation with MDA is essential if GPELF is to
achieve the 2020 target for LF elimination. As the program enters
its 14
th year, the relevance of understanding how to reach
individuals and convince them to comply with MDA has become
increasingly important. While several countries have stopped
MDA and started verification procedures and post-MDA surveil-
lance [9], many LF-endemic countries are still providing MDA or
preparing to start. A better understanding of factors that affect
compliance with MDA at the level of the individual could have
far-reaching effects as programs strive to adapt their campaigns to
more effectively reach their target populations.
Many articles have been published that address the issue of
compliance with MDA for LF. This paper reports results of a
thorough review of publications and unpublished information on
this important subject. The goal of this review was to attempt to
identify factors and patterns that are associated with compliance
with MDA that apply across countries and cultures. We have also
attempted to identify high-priority topics for additional research
on compliance. Improved understanding of factors that affect an
individual’s compliance should be helpful not only for LF
elimination activities but also for integrated NTD programs that
employ MDA and/or preventive chemotherapy.
Methods
A systematic search of 13 databases including PubMed,
Medline, EMBASE, and CAB Abstracts was performed using
the key words ‘‘compliance,’’ ‘‘non-compliance,’’ ‘‘predictor,’’
‘‘factor,’’ ‘‘acceptance,’’ or ‘‘refusal’’ and ‘‘lymphatic filariasis,’’
‘‘elephantiasis,’’ or ‘‘filarial’’ and ‘‘MDA,’’ ‘‘treatment,’’ ‘‘chemo-
therapy,’’ or ‘‘treatment coverage.’’ Papers published in English or
French from 2000 through March 2012 were considered. The
search generated 404 citations, and a preliminary review of title
and abstract was performed using a flowchart for the first
screening. In the second review, 86 papers were read in full.
Those papers that met one of the following criteria were included
in the final dataset: i) reviewed the literature on compliance with
MDA for LF; ii) described or assessed factors associated with
compliance with MDA for LF; iii) analyzed, observed, or
documented compliance rates with MDA and/or provided an
explanation or discussion of the rates; and iv) were identified from
reference lists of primary papers. In addition to the published
literature, informal interviews were conducted with five senior LF
scientists who were selected based on their broad international
experience and knowledge of issues surrounding compliance.
These phone discussions provided the opportunity to solicit
unpublished data and reports for inclusion in this review.
A data extraction form was created using Microsoft Excel to
enable a systematic analysis of the relevant themes arising from the
literature.
Definitions
For the purposes of this paper, coverage is defined as the
percentage of targeted persons who receive MDA medications,
and compliance refers to the percentage of a targeted population
who swallow the medications. Unless otherwise stated, MDA refers
to mass drug administration at the community level; and low or
inadequate compliance is described as ,65%. See Table 1 for
more details of definitions used in this paper.
Results
The search of published literature produced 79 papers that met
criteria for inclusion in this review. Unpublished literature and
data were provided from studies performed in four different
countries (Haiti, Dominican Republic, Cameroon, and Egypt) for
review. Additional data on compliance were contributed from
small surveys conducted in Malaysia, Togo, Mali, and Niger.
Study Characteristics
Types of study design included self-reported questionnaires,
coverage surveys, household surveys, and intervention studies.
Countries where published research was performed included (in
order of most to least frequent): India (n=40), Haiti (n=7), Sri
Lanka (n=5), Papua New Guinea (n=5), Kenya (n=4), Indonesia
(n=3), Tanzania (n=2), Sierra Leone (n=1), Vanuatu (n=1),
Ghana (n=1), Togo (n=1), American Samoa (n=1), Egypt
(n=1), and the Philippines (n=1). Six papers included in the
review were from multi-country or non-specific settings.
Factors Associated with Coverage and Compliance
The reviewed publications used varied definitions for coverage
and compliance. Fifteen studies provided quantitative results for
factors demonstrated to be associated with compliance (Table S1).
However, the majority of the papers reviewed provided qualitative
results and anecdotal data for factors associated with compliance
(Table S2).
Low MDA compliance may be related to the MDA delivery
system and/or to characteristics of targeted recipients. For the
purposes of this paper, the delivery system refers to those who
distribute the MDA drugs at various levels (national, provincial,
district, community, and individual drug distributors), and
recipients are those individuals who are targeted to receive
MDA in an endemic area. Results are presented according to their
relation to the delivery or recipient side of the MDA equation.
Program and Delivery Issues
Problems with availability of drugs and/or promotional
materials were cited as reasons for inadequate coverage in several
Author Summary
Lymphatic filariasis (LF, also known as ‘‘elephantiasis’’) is a
deforming and disabling disease that is caused by
roundworm parasites that are transmitted by mosquitoes.
The Global Programme to Eliminate Lymphatic Filariasis is
the largest public health intervention program attempted
to date based on mass drug administration (MDA). MDA
does not cure filarial infections, but it can reduce or
interrupt transmission of new infections by clearing larval
parasites from human blood so that they are not available
for mosquitoes. High levels of participation are required
for this strategy to work; guidelines from the World Health
Organization call for at least 65% of the eligible population
to take the medications annually for four to six years. MDA
presents logistical challenges that require cooperation
between donors, health ministries, and communities. The
success of MDA depends on coverage (drug delivery) and
compliance (people ingesting antifilarial drugs), which
depends on individual interactions between drug distrib-
utors and the people who live in LF-endemic areas. This
paper focuses on this last step of implementation with a
comprehensive review of published and unpublished
information on factors that affect compliance with MDA
at the level of the individual. We have also provided an
outline of current gaps in understanding and recommen-
dations for further research.
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to low MDA coverage rates in Vanuatu [15] and in East Godavari
district in India [16]. Inappropriate distribution time was
sometimes cited as negatively affecting coverage. In one Indian
study, MDA was postponed and rescheduled to take place during a
major Hindu fasting festival, and this made it difficult for
distributors to reach individuals for directly observed treatment
(DOT) [12]. In another Indian study from Kerala state, repeated
postponement of the MDA resulted in poor coverage and high
rates of non-compliance [17]. In other cases, insufficient time and
personnel adversely affected coverage and compliance [13,14,
18,19].
The absence of eligible recipients of the drugs during MDA due
to short- or long-term migration provided challenges to coverage
in some areas [12,19,20]. However, absence at the time of drug
distribution was also a commonly reported cause for non-
compliance by persons who were not migrants [11,12,15,21–31].
It seems that the time allocated for MDA and for mopping-up
activities was sometimes not sufficient to reach even those people
who were not away at the time of drug distribution [16,18,32].
Good coverage in one year sometimes had a positive effect on
coverage in subsequent years. One study reported that health
workers in the Philippines were especially motivated to reach their
coverage target as a result of seeing a reduction of LF cases in the
community [33]. In the same study, those individuals who had
awareness about LF (p=0.01) and awareness about MDA
(p=0.02) as well as awareness that MDA was associated with
LF (p=0.01) were more likely to have received the drug. Other
factors that were positively associated with good coverage included
good coordination among health staff [11] and the introduction of
Filaria Prevention Assistants (FPA) or community drug distributors
(CDD) to augment the distribution potential of the health services
[13,18,34,35].
Delivery mechanisms. A number of factors related to
details of how drugs were delivered affected compliance in the
reviewed studies. These included the identity of the drug
distributor, the time of day MDA was carried out, the use of
community organizations, the training of the health workers and
drug distributors, motivation of health staff, and the use of DOT.
These elements were repeatedly cited in reviewed studies as having
an impact on compliance with MDA.
Drug distributors are at the interface between MDA programs
and their target populations. Characteristics of these frontline
workers were identified as a key factor regarding compliance with
MDA. Compliance tended to be positively affected when the drug
distributor came from the area where he/she was distributing the
drugs [16] or when recipients personally knew the drug distributor
[26]. Conversely when drug distributors came from a different
Table 1. Annotated list of definitions for mass drug administration (MDA) programs used by the World Health Organization and
the research community [84].
Term Definition Source and authors’ comments
At-risk population ‘‘Total population in the endemic implementation unit(s).’’ [84] This number includes the population eligible and ineligible
for MDA.
Directly observed
treatment (DOT)
The only method to assure an individual swallowed a
drug or a combination of drugs.
[47,87] If DOT was not performed, only self-reported compliance
or surveyed coverage can be reported.
Drug coverage ‘‘Proportion of individuals, expressed as a percentage, in
a targeted population who swallowed a drug, or a
combination of drugs.’’
[84] This paper uses the GPELF definition for drug coverage as
the definition for drug compliance.
Epidemiological drug
coverage
(program coverage)
‘‘Proportion of individuals in the implementation unit
who have ingested the MDA drugs of the total
population in the implementation unit.’’
[76,84,88,89] These papers use the GPELF definition for
epidemiological drug coverage as epidemiological drug
compliance. This describes the proportion of individuals (%) in an
at-risk population who swallowed a drug or a combination of
drugs and is used for epidemiological modeling.
Geographical coverage ‘‘Proportion of administrative units that are implementing
MDA of all those that require MDA.’’
[84] The definition is clear and describes drug distribution
independently from drug ingestion.
Ineligible population ‘‘Group of individuals not qualified or entitled to receive
anti-helminthic treatment in preventive chemotherapy
interventions. Ineligibility is usually determined by
exclusion criteria based on drug safety.’’
[84] Members of the ineligible population may be infected, and
their parasites may result in continued transmission.
National coverage ‘‘Proportion of individuals in an endemic country
requiring MDA for LF who have ingested the
appropriate drugs.’’
[84] Unfortunately, this is a theoretical definition, because
programs normally report doses delivered rather than doses
ingested. Furthermore, programs with high national coverage
may have low epidemiological coverage if ineligible populations
are large.
Reported coverage ‘‘Intervention coverage calculated from data reported
by all drug distributors.’’
[84] This number is often much larger than drug coverage or
surveyed coverage.
Surveyed coverage ‘‘A method used to verify reported coverage through use
of population-based cluster survey methods. It is calculated
as the total number of individuals identified by household
survey as having ingested the drugs of the total number of
individuals residing in all the surveyed households about
whom information on drug ingestion could be elicited.’’
[84] Coverage surveys rely on self-reporting by participants.
Results may be affected by incomplete recall or by participants’
assumptions about answers surveyors want to hear.
Target population
for MDA
The population in an implementation unit that is targeted
for treatment. This includes those who are eligible to
receive the drugs based on safety criteria.
[84] The target population plus the ineligible population form the
total at-risk population in an endemic area.
doi:10.1371/journal.pntd.0002447.t001
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positive motivation provided by drug distributors was often cited
as an important factor that affected compliance with MDA
[22,24,25]. For example, compliance was positively affected when
drug distributors took the medication directly in front of the
community [16]. Similarly, if drug distributors visited the
household at least one time (or more) prior to MDA, this
increased the probability of drug uptake in those households [13].
Some papers reported that direct participation of health
personnel in drug distribution positively influenced MDA
[36,37]. In the Philippines, surveyed individuals reported that
they complied because they had accepted the health worker’s
advice [33]. Similarly, in one study from India, compliance was
5.6 times (95% confidence interval (CI) 3.4–9.1) better when MDA
was distributed by staff from a local health center [38].
Interactions between health workers and the community some-
times motivated village leaders to participate stressing the
‘‘necessity of their cooperation’’ [16].
The involvement of community organizations and other
preexisting networks in MDA distribution sometimes had positive
or negative effects on compliance. In several sites, the involvement
of community groups or networks in the distribution of drugs
improved compliance, because they were able to reach community
members efficiently and effectively and thereby enhance partici-
pation [11,39,40]. The Department of Health in American Samoa
evaluated the territory’s MDA campaign after inadequate
compliance rates (49%) were reported. Following the department’s
recommendations, subsequent MDAs incorporated churches in
the promotion and distribution of the tablets, and this significantly
improved compliance rates to between 65% and 86% over the
subsequent four years of the program [41]. In contrast to this
experience, Aswathy et al. reported that people’s fears were
exacerbated when members of local self-help groups in India acted
as drug distributors, because they were too hurried to answer
people’s concerns about adverse events [42]. Low motivation by
drug distributors was also mentioned as contributing to low
compliance in a report from another area in India, where
overburdened local health workers considered the MDA program
to be an unwelcome additional duty [16]. Similarly in a study from
Kenya, drug distributors cited lack of supervision from health staff,
short training, lack of incentives, and delays in supplies as reasons
for low motivation [43].
Inadequate training of health workers and drug distributors can
have negative effects on MDA compliance. Some reports
mentioned that pills were sometimes dropped off at the house
[11] or left for family members to distribute without an adequate
explanation [12,14]. In a study from Sri Lanka, individuals
reported that they did not like receiving drugs from volunteers,
because the volunteers lacked information about the drugs. Also,
in some cases volunteers were considered to be too young to be
distributing drugs. In the same study, volunteer distributors might
have had more credibility if they had arrived with a badge or an
official letter [26]. In an Indian study, drug distributors’ poor
communication skills were credited with contributing to poor
compliance as people doubted their ability to assess eligibility for
DEC [38]. While some of these issues may not have been directly
related to poor training, improved training and supervision may
have improved performance.
The private health sector can have an important influence on
compliance with MDA. One study from India reported that
private practitioners exaggerated the possible adverse events of
MDA, and this discouraged people from taking the pills [44].
Other reports mentioned that when medical practitioners were not
involved in the MDA process, they remained unaware of the
benefits and necessity of MDA and sometimes advised their
patients against compliance [45,46]. In other cases, community
participation was positively affected when practitioners took the
pills in public and actively supported the program (authors’
unpublished observations).
Although directly observed drug administration is recom-
mended for MDA programs (DO-MDA), it was infrequently used
in the studies reviewed for this paper. MDA programs tended to be
highly successful when DO-MDA was systematically employed
[34,41,47]. One of the difficulties of ensuring DO-MDA was the
perceived challenge of reaching individuals after meals so they
could avoid taking the medications on an empty stomach
[13,14,37].
MDA medication issues. Many studies reported concerns
from individuals about the pills provided during MDA as reasons
for non-compliance. The large number of pills to be swallowed
was cited most frequently, and this was followed by complaints
about the size and taste of the pills [13,15,16,48–50]. There were
also concerns about the quality of the drugs. One report from
Haiti mentioned that the pills were ‘‘bad’’ [23], while one paper
from India mentioned that the pills had disintegrated into powder
[30]. The distribution of ‘‘loose tablets’’ was also cited as a reason
not to comply with MDA [17,22].
Individual Recipient Characteristics
Awareness and knowledge. One of the most prominent
factors associated with motivating compliance and increasing
coverage was advance knowledge of the MDA, as demonstrated in
studies from India, Sri Lanka, the Philippines, Sierra Leone, and
Vanuatu [15,18,25,26,33,51,52]. The inverse of this was also
observed, when individuals did not comply because they were
unaware of the MDA or the LF elimination program
[13,19,22,53].
Across the literature, knowledge associated with compliance was
primarily related to three specific topics: transmission of LF,
knowledge that MDA protects against LF, and knowledge of
lymphedema management techniques. Knowing that mosquitoes
are responsible for the transmission of LF was shown to be
associated with compliance in several studies [24,26–28,51,54].
Ramaiah et al. described the inverse of this phenomena whereby
people were unwilling to comply because they reported that they
controlled mosquitoes in their own living environments and
therefore were not at risk for LF [55]. Those individuals who
reported knowing that MDA medications prevented LF were also
more likely to comply [13,15,16,22,24–26,33,39,42,53].
In studies that performed multivariate analysis, knowledge that
MDA was for LF was a key factor associated with compliance
[24,25]. One Indian study reported a strong association between
compliance and the interaction between knowing about MDA in
advance and knowing that everyone was at risk for LF (odds
ratio (OR) 16.1; 95% CI 8.8–29.3) [25]. Another Indian study
demonstrated that the combination of advanced knowledge of
MDA and knowing that mosquitoes transmit LF dramatically
increased the probability of a person complying with MDA [24].
Finally, there was evidence that knowledge of lymphedema
management techniques and the availability of case management
programs for diseased individuals (lymphedema management pro-
grams and hydrocele surgery) improved compliance with MDA
[25,35,51]. For example, establishment of and support for Hope
Clubs in Cap Haitien, Haiti helped to demonstrate that the LF
elimination program had a long-term commitment to help those
affected by LF and that it was not simply a short-term drug
administration program (L. R. Carpenter, personal communication).
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inhibited people’s uptake of MDA medications. For example,
some people in the Philippines believed that the treatment might
cause sterility, fainting, or even death [33]. Uptake of MDA
increased after these misconceptions were corrected. In Tanzania,
misperceptions about MDA resulted in lower compliance rates;
specifically, some people believed the drugs were a contraceptive
while others thought that the pills inhibited libido [56]. Similar
fears that the drugs were contraceptives were expressed in Kenya
[34]. In Vanuatu, some believed that the pills would cause LF and
that the government was trying to sterilize the communities [15].
Compliance also suffered in areas where people were misinformed
about the etiology of LF (believing it to be due to heredity or
caused by a curse) [13] (A. Viall, personal communication, and
authors’ unpublished observations).
Aside from the three primary knowledge indicators discussed
above, there was scant information on further associations
between knowledge and compliance. Detailed knowledge regard-
ing LF and MDA was not always associated with high compliance
with MDA in some areas (Els Mathieu, personal communication,
and authors’ unpublished observations [57,58]).
Understanding the personal risk of LF and the benefits of
MDA. hose individuals who were able to express their own
personal risk for LF were more likely to comply with MDA. In
some papers, this was described as having seen someone with LF
or having someone in the family with LF, while in other cases it
was expressed as an understanding that ‘‘everyone is at risk for
LF’’ [25,26,51]. One study from Sri Lanka demonstrated higher
compliance in urban areas for those who had seen someone with
clinically evident LF [26]. The inverse of this perception was also
demonstrated. That is to say, those who did not perceive LF to be
a problem in their community were less likely to comply with
MDA [12,59,60].
Those who were able to personalize the benefit of the MDA for
their own individual health were likely to be compliers
[16,22,39,42]. Perceived benefit was positively associated with
compliance in studies from India and the Philippines [33,42].
Understanding that the MDA was beneficial was similarly
associated with increased compliance [26]. Note that perceived
benefit of the treatment is not the same as understanding that the
MDA is for LF.
Adverse events and MDA. The potential for adverse events
following MDA was responsible for discouraging as well as
encouraging uptake. Many papers cited individuals in their surveys
who were afraid of adverse events from the treatment and as a
result did not want to comply with MDA [11,13–18,22–
26,30,31,33,37,50,59,61–63]. Some of this fear arose from
inadequate explanations about possible adverse events and a
failure to understand that severe adverse events are rare [42].
Rumors regarding adverse events associated with MDA can
seriously affect compliance by individuals. Three studies from
India and one from Haiti mentioned erroneous reports of deaths
due to MDA that negatively affected compliance [11,28,39,44].
When these rumors were not addressed, they persisted and
negatively affected MDA in neighboring areas as well [12,64].
When communities did not receive correct and adequate
information about adverse events, the consequences were detri-
mental to the success of the MDA. In Orissa, India, insufficient
information about the MDA and its possible adverse events led to
an erosion of confidence in the community, and as a result, the
MDA was postponed for three years [65]. In East Godavari
district, India, MDA was suspended due to adverse events until
health workers intervened and addressed community concerns
[16]. On the other hand, in areas where the management of
adverse events was monitored and well coordinated in commu-
nities, individuals cited this as positively influencing their
acceptance of MDA and suggested that the possibility of adverse
events did not inhibit their participation in MDA [16,66].
Similarly there were some instances where those who experienced
adverse events following MDA in one year were more likely to
comply the following year [67,68]. Anecdotal evidence from Alor
district, Indonesia suggested that some individuals equated adverse
events with evidence that the treatment was effective [57].
However, adverse events following MDA in one year sometimes
deterred individuals from compliance in subsequent years [27,67].
The elimination of intestinal helminths was cited in several
papers as a positive consequence of MDA [69,70]. This
deworming effect was perceived to be a community benefit, and
this contributed to overall community acceptance of the MDA
program. For example, Talbot et al. found that Haitian subjects
who did not know that the pills contained albendazole (ALB) were
five time more likely to be non-compliant than those who did
know about ALB, suggesting that the people were aware of the
collateral deworming benefits of this medication [71]. Anecdotal
reports from Indonesia, Papua New Guinea, and Haiti described
individuals who were grateful or even ‘‘excited’’ when they or their
children passed intestinal worms following MDA (L. R. Carpenter,
personal communication, and authors’ unpublished observations).
Recipient’s personal situation. Several publications men-
tioned that personal characteristics influenced compliance with
MDA. Characteristics cited included the individual’s personal
health at the time of drug distribution, whether or not they were
taking other medications, their gender, age, household income, or
residence in urban or rural areas, and as mentioned above, their
understanding of their own personal risk for infection with LF.
Individual health status and current use of medication heavily
affected people’s compliance with MDA. In many instances, papers
cited ‘‘healthy,’’ ‘‘have no LF disease,’’ or ‘‘drugs are unnecessary’’
as reasons for non-compliance among their study populations
[11,13,14,16–19,22,25,26,30,37,39,53,61–63]. Being ill at the time
of MDA was also cited as a reason for non-compliance
[11,16,22,24,25,27,37,39,42]. Furthermore, it was also commonly
expressed that people refused MDA because they were presently
taking other medications (including contraceptives) and that they
were concerned about possible interactions with the LF drugs
[18,23,26,28,30,37,61]. Treatment for other illnesses was the
primary reason given for systematic non-compliance in one study
[39].
Female gender was often associated with lower rates of
compliance with MDA. For example, pregnancy was often cited
as a reason for non-compliance, as pregnant women were not
eligible for MDA, and lactation was considered to be a contrain-
dication to MDAin the early years of the program. In Haiti, women
of childbearing age were excluded at the beginning of the MDA
campaign due to fears of using ALB in early pregnancy. Although
this policy was reversed prior to the third round of MDA, it had a
lasting effect, because women continued to have low compliance
rates [71]. Other reasons cited for low MDA compliance in Haitian
women included a rumor that women should not comply with
MDA if they were taking contraception, fear of miscarriage, and a
desire to avoid embarrassment at MDA distribution posts where
they would be asked if they were pregnant or not (N. Barkey,
unpublished report). In some household situations, women also
were prohibited from seeking or taking MDA, because of their
husbands’ negative beliefs regarding the treatment (authors’
unpublished observations).
Age was closely associated with MDA compliance in some
studies. In most cases, the youngest (under 5 years of age) were the
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parents feared how the treatment might affect their children
[14,23,30,72]. In one study from Egypt, children aged 2–4 years
showed lower rates of compliance than adults. However, this may
have been due to blood tests conducted at the time of the survey
[73]. In a few studies, the elderly were also reported to be
systematic non-compliers [39,40] as were individuals 15–34 years
of age in a Ghanaian study [40] and people aged 16–30 years in
an unpublished report from Haiti (N. Barkey [2009]). Similarly,
Wynd et al. discovered that the younger generation in Papua New
Guinea was becoming resistant to continuing compliance in some
areas, because they thought that LF was no longer a threat [74].
Area of residence and household income often affected
compliance. Living in a rural environment was associated with
higher compliance in several studies [11,13,37,75], while achiev-
ing compliance in urban areas was more challenging. Inadequate
coverage and compliance in urban areas were attributed to some
of the following factors: lack of a specific urban strategy [11,72],
fewer peripheral health workers [72] and volunteers [26], the
dominance of private health care providers [22,55], poor health
care infrastructure [22,55], and the presence of unorganized
settlements and large numbers of migrants [55]. Individuals with
lower incomes were also more receptive to MDA in some urban
areas [55], while those with higher incomes were more difficult to
reach and to convince to take the medications [39,48].
Discussion
A better understanding of factors that influence compliance with
MDA for LF may improve results for current and future MDA
campaigns. This paper has attempted to provide a thorough
review of published information on this topic in the global context,
and that information was supplemented by unpublished data and
interviews with key informants.
It is important to emphasize the importance of definitions and
the distinction between coverage (delivery of the medicines) and
compliance (ingestion of the pills). For example, the WHO collects
reported coverage data from national LF elimination programs.
However, GPELF publications sometimes use reported coverage
data as if they were the same as ‘‘coverage with ingestion of drugs’’
[9]. Another illustration of the importance of these definitions
comes from the computer simulation literature. The LYMFASIM
simulation model uses ‘‘the fraction of people treated per round’’
(equivalent to ‘‘epidemiological drug coverage’’ as defined in
Table 1) as a key input for estimating the impact of MDA on
filarial infection rates and transmission [76]. Important differences
between ‘‘epidemiological drug coverage’’ and ‘‘reported cover-
age’’ may explain the persistence of LF after several years of MDA
in countries despite high reported coverage rates.
One of the limitations of this review is that its primary focus is
on the factors influencing compliance decisions at the individual
level. Little published information is available on how factors such
as program design, management, or implementation might affect
coverage and compliance. Hence, further research is needed in
this area.
The reviewed studies were quite varied in terms of size, location,
and design. Results also varied, and our challenge was to tease out
the common themes. Our review did not identify a specific
compliance recipe that will work in any country or context.
However, the study has identified five key ‘‘ingredients’’ that
appear to be essential for encouraging compliance at the
individual level for successful MDA programs.
1. Acknowledging the Role of Trust in MDA
The issue of trust permeates many of the factors and specific
experiences that are associated with compliance or non-compli-
ance. Specifically, individuals need to trust the person(s)
delivering the drugs to them and communities need to trust the
health workers and governments promoting and directing the
MDA. As a result, elimination programs need to ensure that
elements of trust are built into campaigns so as to effectively
engage with communities. Some of these elements are outlined in
Figure 1 and discussed below.
It is impossible to overemphasize the importance of the face-to-
face interaction between the drug distributor and the individual
who receives the medicine. Recipients may be reassured,
motivated, discouraged, angered, or confused during this critical
interaction. We found that the identity of the drug distributor was
consistently linked to compliance. The following factors regarding
distributors may build trust in MDA: selection of distributors
known to the community and with reputations or other credentials
to indicate that they can be trusted, adequate training for
communicating knowledge related to MDA, motivation and belief
in the importance of the program, and adequate time for MDA
and a willingness to answer questions. While it is recognized that
the role of the drug distributor is key to the efforts to eliminate LF,
more work is needed to develop protocols to motivate and sustain
the commitment of drug distributors over the long course of MDA
programs.
Government health workers serve as drug distributors in some
communities, and as stated above, many of the same issues apply
to their success at the point of distribution. Since community
members trust their advice, they tend to be successful promoters
of MDA if they provide motivation, have the time to reassure
participants about adverse events, and if they are enthusiastic
about the campaign. Compliance suffers when they are overbur-
dened, unmotivated, and undertrained. Private health providers
could provide a similar service, however they are usually not
systematically involved in the promotion and administration of
the MDA. Engagement of private providers could reduce
Figure 1. Major factors that affect individual compliance with
mass drug administration for elimination of lymphatic filaria-
sis.
doi:10.1371/journal.pntd.0002447.g001
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MDA programs and improve community compliance. Published
literature and WHO guidelines do not describe proven strategies
to enhance motivation and participation by public or private
health care workers in MDA programs.
At the onset of MDA programs, consideration of several
programmatic components is warranted in order to cultivate trust
between the health services and the recipient communities—
namely timely promotion of MDA, adequate management of
adverse events, and recognition of other pressing health needs in
the community. Each of these elements has been shown to
enhance individual compliance with MDA. Across international
contexts, advance knowledge of MDA was positively associated
with ingestion of the pills. In order to promote MDA effectively
and to encourage the establishment of the social norm of
compliance, information about the pills and their distribution
needs to be made frequently available before MDA begins to foster
an environment of trust between the delivery system and the
recipient. For communities to be effectively engaged in the
elimination of LF, evidence shows that they need to hear about the
MDA not only from the health services, but also from local leaders
(cultural, religious, village), household authority figures, and from
Table 2. A basic troubleshooting guide for commonly encountered problems in MDA programs.
Scenario Description of issue Suggested areas for intervention
Low reported coverage Drugs are not reaching targeted population. 1. Who are drug distributors—are they appropriate for the
community?
2. Check motivation of drug distributors in terms of
incentives, training, logistical capacity.
3. Assess security situation and time of MDA.
4. Is the distribution method appropriate?
5. Check reporting forms and systems.
High reported coverage with low drug
coverage (e.g., compliance with treatment)
Drugs distributed to targeted population
are not being swallowed.
1. Consider how DO-MDA can be implemented (time of day
for MDA, distribution method).
2. Assess level of awareness about MDA in the community;
should novel communications be introduced (cell phones,
social media)?
3. Are local leaders and groups involved in the process?
4. Assess fear and management of adverse events.
5. Evaluate role and reputation of health services in the
population.
High rates of systematic non-compliance Individuals have not ingested the drugs
in any MDA round.
1. Identify subgroups with high non-compliance rates and
design programs to target these groups.
2. Consider a test-and-treat approach.
3. Use of behavior change models to address persistent non-
compliance (e.g., motivational interviewing).
Local health system (at IU level) weak and
unable to conduct MDA
Local health system weakened due to lack
of personnel, funds, or post-conflict situation.
1. Identify local NGOs or organizations who would be capable
of conducting MDA in a specific IU.
2. Where logistics are challenged, identify possible private
sector participants to fill the gap.
Reported coverage decreasing as MDA
rounds continue
Drugs are not reaching the population as MDA
continues.
1. Consider health service personnel and drug distributor
fatigue and how to address it.
2. Has there been a change in local management?
3. Has there been a change in logistical provision?
Drug coverage decreasing as MDA rounds
continue
Individuals who may have taken drugs in previous
rounds are refusing to comply with treatment.
1. Has there been a population increase to affect the
denominator?
2. Are there persistent rumors affecting the campaign?
3. Are adverse events being adequately managed?
4. Assess drug distributors’ ability to respond to questions,
fears.
High reported coverage and low surveyed
coverage
Drug distributors report distributing adequate
number of drugs to the targeted population,
but independent coverage surveys report lower
rates of drug coverage or compliance.
1. Check reporting forms and systems.
2. Review possible population shifts.
3. Consider how DO-MDA can be implemented (time of day
for MDA, method of distribution).
4. Assess security situation and timing of MDA.
5. Is the distribution method appropriate?
doi:10.1371/journal.pntd.0002447.t002
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persons in MDA enhances confidence in the MDA program and
further promotes its individual and collective benefits.
In 2000 when the GPELF was launched, it stood on two pillars—
MDA and morbidity management. In the majority of the papers
reviewed here, there was little discussion or evidence that morbidity
management had been implemented as a complement to MDA.
From evidence in India, Haiti, Indonesia, and Zanzibar, it is clear
that lymphedema management programs and hydrocele surgeries
lend credibility to MDA programs. Aside from the benefit to MDA,
there is clear evidence that these programs also alleviate the
suffering caused by the long-term manifestations of LF and tangibly
improve the lives of patients and their families [77].
Many articles mentioned that fear motivates many people not to
take the tablets. If the components discussed above can be put into
place before MDA begins, then this can help to alleviate fears and
anxieties by establishing an environment of trust to increase
chances for a successful program.
2. Tailoring a Distribution System That Is Appropriate to
the Local Environment
MDA occurs in many different contexts around the world and
also within countries and regions. These contexts reflect varied
histories, local culture, and the impact of local leaders. Programs
that strive to work together with leaders and that try to understand
and respect their beliefs, trust networks, and fears will have better
chances for success. In addition, programs should be planned so
that MDA begins only after drugs, promotional materials, and
personnel are available and in place. Delays in distribution can
confuse communities and provide opportunities for rumors to arise
and persist that may hamper compliance with MDA when it
finally arrives. Social scientists have recommended comprehensive
anthropological studies as prerequisites to MDA [78]. While the
results of these studies may well enhance the planning of MDA,
time, money, and expertise are not always available to carry them
out. When such studies are not feasible, programs can look to
other health agencies working in the same area to learn from their
Table 3. Research needs and gaps in understanding.
Key area and topic Associated questions Suggested methods
A. Service delivery
1. Relationship between the delivery system
and the recipient and how that affects
compliance
What is the role of the delivery mechanism in
achieving compliance? How to train, supervise,
motivate, and empower drug distributors?
Participant observation of MDA, semi-structured
interviews, coverage surveys, pilot study
2. Interactions at the point of delivery/
distribution
What conditions are necessary to enhance compliance?
What happens at the point of distribution?
Participant observation, semi-structured interviews
3. Operational considerations to ensure
the use of DO-MDA
What factors must be considered to achieve DO-MDA?
Are there best practices to promote?
Literature review, surveys with health staff and
community members, pilot study
4. Best practices for MDA What is working in different contexts? How can this
information be collated and shared with program
managers to enhance their control efforts?
Identify best practices globally through literature
review, discussions with key informants, prepare
case studies, disseminate results at scientific
meetings
5. Innovative approaches to enhance social
mobilization and drug delivery
Explore use of social media, mobile phone technology,
NGO networking, outsourcing, use existing networks
(e.g., HIV/AIDS infrastructure, community health workers)
Case studies to test new methodologies in a way
that can be evaluated and replicated
B. Strategic issues for LF and other NTD programs
1. Integration of the lessons learned from
GPELF into NTD programs
What are the key lessons from 12 years of GPELF?
How might they be applied to NTD programs?
Literature review, interviews with key informants
2. Sharing of research results and operational
knowledge to and in between members of
the GPELF community
How is knowledge shared between programs? How can
sharing be enhanced?
Key informant interviews, exploration of new
formats to share information
3. Understanding the changing dynamics of
six or more years of MDA in a community/
district/country
What changes might programs expect over time
(fatigue, misperceptions, funding, societal changes)
and how to address those?
Document experiences from MDA programs after
six or more years and how they adapted to
changing conditions
4. Focus on difficult and challenging
environments for MDA and identify solutions
for improved coverage and compliance
What are the current difficult environments? What
tools can be used to reach these people? How can
populations be segmented for mobilization?
Pilot studies
5. Integration of LF elimination and NTD
programs
How should social mobilization reflect NTD
integration? M&E? How does introduction of other
NTD programs affect ongoing MDA for LF?
Literature review, key informant interviews
C. Compliance and the individual
1. The impact of systematic non-compliers
(SNC) and how to reach them
Who are SNC? What are their characteristics? What
can be done to convince them to comply with MDA?
Literature review, key informant interviews, pilot
studies to test specific interventions
D. Compliance and the community
1. Understanding the impact of morbidity
management on compliance
Why does morbidity management influence compliance?
How can it be promoted and sustained? Does it have
the same effect across contexts?
Literature review, key informant interviews
2. Engaging the community in an urban
environment
What social groups can be activated for MDA in urban
areas? What is the best way to conduct DO-MDA in
these environments?
Pilot studies, literature review
doi:10.1371/journal.pntd.0002447.t003
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child health programs) and adapt the MDA accordingly.
While several studies have emphasized the importance of DO-
MDA, it is more the exception than the rule within GPELF. More
effort in this area is needed to ensure that individuals actually
swallow the tablets that are distributed to reduce the gap between
coverage and compliance. Planners should consider the habits of
community members, their work, and social schedules including
meal times. Drug distributors must be trained on procedures to
follow when they encounter non-compliers. Options might include
referral to a supervisor or scheduling a time for a second visit when
there is more time for questions and discussion. This type of
activity increases the time and effort for drug distribution, and this
should be taken into account when planners consider time and
budgets for drug distribution.
3. Management of Adverse Events
Adverse events (AEs) following MDA are generally mild, and
the frequency of AEs decreases after the first round of MDA [79].
However, our literature review showed that fear of AEs is one of
the major reasons people do not comply with MDA. Furthermore,
residual apprehension about the possibility of AEs may persist in
an area even after the frequency of such events has declined [23].
As a result, programs should be vigilant when planning MDA and
in the early years of MDA to ensure that health services are
prepared to handle minor AEs as they arise. Management of AEs
in these first years of treatment will benefit the program in
subsequent years, as this will reassure communities that the drugs
are safe and that the health services can be trusted. In the same
vein, community drug distributors need be aware of how AEs will
be managed so they can clearly communicate plans for this with
communities and individuals as they distribute the pills.
The positive side effects (so-called ‘‘ancillary benefits’’) of MDA
need to be communicated and reiterated during the pre-MDA
socialization as well as at the time of pill distribution. The
clearance of soil-transmitted helminths is a major associated
benefit of MDA, particularly in children. Drug distributors should
convey this information to community leaders and to families so
that they can use this information to increase acceptance of MDA.
4. Promotion of Other ‘‘Non-Health’’ Benefits of
Compliance
Traditionally, awareness campaigns stress the functional bene-
fits of a cure or treatment that heals sickness or prevents disease.
Generally speaking, health officials and workers consider health to
be an adequate motivation to achieve participation or compliance.
However, the promise of health may not be a strong motivator in
areas where clinically evident LF is uncommon. In many of the
papers reviewed, the prospect of being cured or preventing LF was
infrequently named as the primary reason people complied with
treatment.
While the health benefits of MDA may indeed influence some to
take the treatment, the non-health benefits may be equally
influential on behavior. Therefore campaigns should make every
effort to promote intangible benefits associated with the treatment.
These might include: feeling modern by accepting non-traditional
medicines, being perceived as someone who cares about his family
and health, being seen as someone who fits in with others in the
community, being a good citizen and following the government
program, being smart and preventing future economic loss,
protecting future generations from LF, or feeling safer. Promotion
of additional benefits of MDA may stimulate demand for the
tablets.
To illustrate this further, the association between LF and a cycle
of poverty has been well documented [80]. Those living with
chronic filariasis suffer from acute attacks that require them to
forgo work for a period of time and seek medical assistance. Those
with elephantiasis, lymphedema, or hydrocele may also suffer from
associated stigma [5,81]; the emotional burden of these conditions
is only just starting to be understood [82]. With this knowledge in
mind, promotion of MDA should address the economic and social
benefits of treatment. Understanding the everyday economic
benefits of LF elimination at the household level may persuade
some individuals to comply. Furthermore, when discussing LF
elimination with government health officials, the importance of
these economic savings over the long term for endemic districts
should be part of the promotion and advocacy activities.
Children under five years of age were identified as systematic
non-compliers in several studies from areas where MDA is
provided to children starting as young as two years of age.
Publicity regarding the deworming effects of MDA (with the
associated improvements in general health, school attendance, and
growth) may be useful for countering this problem. If parents
understand that MDA has these benefits in addition to anti-LF
properties, this may tip the balance in favor of participation. It
may also be helpful to explain that the time-limited MDA program
aims to provide a healthier and safer environment for all future
children and generations. For example, a paper published in 2011
stated that MDA had already protected 66 million newborns from
acquiring LF [83].
5. Addressing the Issue of Systematic Non-Compliance
Systematic non-compliers have been identified as persons who
persistently refuse or do not ingest antifilarial medications over the
multi-year course of an MDA program. Non-compliers can serve
as a continued source of infection that may place their community
at continued risk for transmission of LF. This has been
demonstrated in Haiti and in Egypt, where those who reported
never taking MDA had higher infection rates than compliant
persons [23,47]. Therefore further work is needed to identify
systematic non-compliers and their motivations. Explanations will
vary in different locations, but special attention should be paid to
the issues of seasonal migration and low compliance in young
children. When groups with high rates of systematic non-
compliance are identified, specific approaches are needed to
counter factors that result in non-compliance. There is an urgent
need to develop guidelines for managing this problem, as none
currently exist.
Areas Recommended for Further Research
Concepts of coverage and compliance. Since definitions
and equations for coverage and compliance varied in the papers
reviewed for this study, it was challenging to compare results and
experiences across different papers. It would be helpful if
researchers and national programs could agree to a uniform set
of definitions. The definitions in the most recent guidelines from
WHO [84] (reprinted in Table 1) are a good starting point.
However, we believe that the definitions in this document should
be modified to clarify the distinction between coverage and
compliance. Most of the publications reviewed for this paper use
the term ‘‘compliance’’ to describe what is called ‘‘drug coverage’’
in the guidelines. As this contributes to confusion, the authors
propose that the term ‘‘compliance’’ should be included as another
term for ‘‘drug coverage’’ in the guidelines to improve clarity and
understanding.
A ‘‘tool box’’ for difficult areas. LF elimination is
progressing well in many countries. However, special approaches
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that are not meeting expectations. These often face special
challenges such as difficult access, post-conflict health systems and
populations, post-natural-disaster environments, large urban
settings, and fragmented societies. They may include areas that
have failed transmission assessment surveys (TAS) despite many
years of MDA. New tools are needed to help LF programs to
quickly assess the characteristics of these challenging environments
and plan MDA or other responses accordingly. When standard
approaches are not achieving the goal, other resources (private
sector or other donors) and implementation partners (faith-based
organizations, NGOs) may tip the balance toward success. By
approaching these more challenging areas intentionally and
differently, a troubleshooting guide may be helpful to guide
assessment, execution of MDA, monitoring, and evaluation. A
basic troubleshooting guide is presented in Table 2 with suggested
tools. This can be adapted for local use, and it should be modified
over time based on feedback regarding its use.
Gaps in understanding. Areas that have been identified that
require additional research fall into four categories: service
delivery, strategic issues for NTD programs, and compliance at
the level of the community and the individual (Table 3). This
review has identified gaps in understanding related to service
delivery and program strategy. Some of these are related to the
recent move to integrate programs for diverse NTDs that vary
with regard to intervention tools, target populations, and goals
(control versus elimination). More work is needed to improve
understanding of the impact of this integration on LF elimination
efforts so that the benefits of integration can be harvested while
minimizing the risks that integration may pose to GPELF.
Final Conclusions
There is a sense of urgency to some of the issues raised in this
paper. The clock is ticking for the elimination of LF by 2020.
Through unprecedented pharmaceutical donations, the drugs for
MDA are ready and available for use by national programs. The
focus should now move from the issue of supply to the question of
how to best deliver precious donated drugs into the mouths of
those living in endemic areas. The success of the global program
hinges on sufficient and sustained compliance, which is achieved
one person at a time. The risks of insufficient compliance are too
great to ignore. These include the possible emergence of drug
resistance [85], the potential need for additional rounds of
treatment [76] with their associated costs, and the risk of program
fatigue at the community and health service levels. With seven
years remaining, focused attention is needed to optimize MDA in
countries that are just starting their programs and to improve
ongoing campaigns in countries where compliance has been less
than adequate. Finally, in light of the London Declaration of 2012
[86] and the increased global commitment to eliminate or control
NTDs, it will be important to share and integrate lessons learned
from various NTD programs regarding compliance and behav-
ioral change to maximize the benefit of these interventions for at-
risk populations.
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